Literature DB >> 14553837

Vascular endothelial growth factor-D expression in human atherosclerotic lesions.

Juha Rutanen1, Pia Leppänen, Tiina T Tuomisto, Tuomas T Rissanen, Mikko O Hiltunen, Ismo Vajanto, Mari Niemi, Tomi Häkkinen, Kari Karkola, Steven A Stacker, Marc G Achen, Kari Alitalo, Seppo Ylä-Herttuala.   

Abstract

OBJECTIVE: Vascular endothelial growth factor-D (VEGF-D) is a recently characterized member of the VEGF family, but its expression in atherosclerotic lesions remains unknown. We studied the expression of VEGF-D and its receptors (VEGFR-2 and VEGFR-3) in normal and atherosclerotic human arteries, and compared that to the expression pattern of VEGF-A.
METHODS: Human arterial samples (n=39) obtained from amputation operations and fast autopsies were classified according to the stage of atherosclerosis and studied by immunohistochemistry. The results were confirmed by in situ hybridization and RT-PCR.
RESULTS: We found that while VEGF-A expression increased during atherogenesis, VEGF-D expression remained relatively stable only decreasing in complicated lesions. In normal arteries and in early lesions VEGF-D was mainly expressed in smooth muscle cells, whereas in complicated atherosclerotic lesions the expression was most prominent in macrophages and also colocalized with plaque neovascularization. By comparing the staining profiles of different antibodies, we found that proteolytic processing of VEGF-D was efficient in the vessel wall. VEGFR-2, but not VEGFR-3, was expressed in the vessel wall at every stage of atherosclerosis.
CONCLUSIONS: Our results suggest that in large arteries VEGF-D is mainly expressed in smooth muscle cells and that it may have a role in the maintenance of vascular homeostasis. However, in complicated lesions it was also expressed in macrophages and may contribute to plaque neovascularization. The constitutive expression of VEGFR-2 in arteries suggests that it may be one of the principal mediators of the VEGF-D effects in large arteries.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14553837     DOI: 10.1016/s0008-6363(03)00518-2

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  18 in total

1.  Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2.

Authors:  Francescopaolo Granata; Annunziata Frattini; Stefania Loffredo; Rosaria I Staiano; Angelica Petraroli; Domenico Ribatti; Rob Oslund; Michael H Gelb; Gerard Lambeau; Gianni Marone; Massimo Triggiani
Journal:  J Immunol       Date:  2010-03-31       Impact factor: 5.422

2.  Differential mRNA and tissue expression of lymphangiogenic growth factors (VEGF-C and -D) and their receptor (VEGFR-3) during tail regeneration in a gecko.

Authors:  Helen A Blacker; Sandra Orgeig
Journal:  J Comp Physiol B       Date:  2011-07-29       Impact factor: 2.200

3.  Localisation of lymphatic vessels and vascular endothelial growth factors-C and -D in human and mouse skeletal muscle with immunohistochemistry.

Authors:  Riikka Kivelä; Eino Havas; Veikko Vihko
Journal:  Histochem Cell Biol       Date:  2006-08-19       Impact factor: 4.304

Review 4.  Revelations About Aging and Disease from Unconventional Vertebrate Model Organisms.

Authors:  Yang Zhao; Andrei Seluanov; Vera Gorbunova
Journal:  Annu Rev Genet       Date:  2021-08-20       Impact factor: 16.830

5.  Creation, validation, and quantitative analysis of protein expression in vascular tissue microarrays.

Authors:  Marc K Halushka; Toby C Cornish; Jie Lu; Steve Selvin; Elizabeth Selvin
Journal:  Cardiovasc Pathol       Date:  2009-02-11       Impact factor: 2.185

6.  A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C.

Authors:  Maria G Stathopoulou; Amélie Bonnefond; Ndeye Coumba Ndiaye; Mohsen Azimi-Nezhad; Said El Shamieh; Abdelsalam Saleh; Marc Rancier; Gerard Siest; John Lamont; Peter Fitzgerald; Sophie Visvikis-Siest
Journal:  J Lipid Res       Date:  2012-12-02       Impact factor: 5.922

7.  Dose-dependent response of FGF-2 for lymphangiogenesis.

Authors:  Lynn K Chang; Guillermo Garcia-Cardeña; Filip Farnebo; Michael Fannon; Emy J Chen; Catherine Butterfield; Marsha A Moses; Richard C Mulligan; Judah Folkman; Arja Kaipainen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

8.  The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.

Authors:  Nicole C Harris; Natalia Davydova; Sally Roufail; Sophie Paquet-Fifield; Karri Paavonen; Tara Karnezis; You-Fang Zhang; Teruhiko Sato; Julie Rothacker; Edouard C Nice; Steven A Stacker; Marc G Achen
Journal:  J Biol Chem       Date:  2013-02-12       Impact factor: 5.157

9.  Novel vascular endothelial growth factor D variants with increased biological activity.

Authors:  Pyry I Toivanen; Tiina Nieminen; Lenita Viitanen; Annamari Alitalo; Miia Roschier; Suvi Jauhiainen; Johanna E Markkanen; Olli H Laitinen; Tomi T Airenne; Tiina A Salminen; Mark S Johnson; Kari J Airenne; Seppo Ylä-Herttuala
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

10.  Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis.

Authors:  Taina Vuorio; Harri Nurmi; Karen Moulton; Jere Kurkipuro; Marius R Robciuc; Miina Ohman; Suvi E Heinonen; Haritha Samaranayake; Tommi Heikura; Kari Alitalo; Seppo Ylä-Herttuala
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-04-10       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.